Multiple Sclerosis Clinical Trials in Los Angeles

Showing 401-420 of 489 trials

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

NCT01002222

This is an open-label extension study of another study protocol, MCS-2-US-a. Subjects who have completed the 12-week treatment and procedures under the protocol MCS-2-US-a will be eligible for this study.

Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia

Health Ever Bio-Tech Co., Ltd.200 participantsStarted Jan 2011

Los Angeles, California, United States

COMPLETEDPhase 2/3< 1 mile

MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417

The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

Lower Urinary Tract SymptomsBenign Prostatic Hyperplasia

Health Ever Bio-Tech Co., Ltd.274 participantsStarted Jul 2010

Los Angeles, California, United States

COMPLETEDPhase 2< 1 mile

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

NCT00151034

Purpose: The purpose of this study is to evaluate the efficacy and safety of treatment with trastuzumab (Herceptin) along with the three other chemotherapy drugs, paclitaxel, carboplatin and gemcitabine, in patients who have advanced urothelial cancer. This clinical trial will also collect information (alternative therapy, response rates, overall survival) from enrolled patients with HER2 negative tumors who are ineligible to receive study treatment.

Urologic Neoplasms

University of Michigan Rogel Cancer Center33 participantsStarted Sep 2000

Duarte, California, United States • Los Angeles, California, United States • Sacramento, California, United States +8 more locations

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

MCS in the Treatment of Lower Urinary Tract Symptoms

Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer

Multiple Sclerosis Trials in Other Cities

NP2 Enkephalin For Treatment of Intractable Cancer Pain

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

PRISM Registry: Pseudobulbar Affect Registry Series

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

Treatment Interruption of Natalizumab

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT

Other Conditions in Los Angeles